JP2004041195A5 - - Google Patents

Download PDF

Info

Publication number
JP2004041195A5
JP2004041195A5 JP2003169309A JP2003169309A JP2004041195A5 JP 2004041195 A5 JP2004041195 A5 JP 2004041195A5 JP 2003169309 A JP2003169309 A JP 2003169309A JP 2003169309 A JP2003169309 A JP 2003169309A JP 2004041195 A5 JP2004041195 A5 JP 2004041195A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
protein
amino acid
acid sequence
inhibitory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003169309A
Other languages
English (en)
Japanese (ja)
Other versions
JP3935861B2 (ja
JP2004041195A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003169309A priority Critical patent/JP3935861B2/ja
Priority claimed from JP2003169309A external-priority patent/JP3935861B2/ja
Publication of JP2004041195A publication Critical patent/JP2004041195A/ja
Publication of JP2004041195A5 publication Critical patent/JP2004041195A5/ja
Application granted granted Critical
Publication of JP3935861B2 publication Critical patent/JP3935861B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003169309A 1997-04-15 2003-06-13 新規蛋白質及びその製造方法 Expired - Lifetime JP3935861B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003169309A JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02
JP2003169309A JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP54374198A Division JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004381995A Division JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法

Publications (3)

Publication Number Publication Date
JP2004041195A JP2004041195A (ja) 2004-02-12
JP2004041195A5 true JP2004041195A5 (enExample) 2005-08-04
JP3935861B2 JP3935861B2 (ja) 2007-06-27

Family

ID=27525882

Family Applications (7)

Application Number Title Priority Date Filing Date
JP54374198A Expired - Lifetime JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法
JP2003169309A Expired - Lifetime JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP54374198A Expired - Lifetime JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Country Status (21)

Country Link
US (7) US7527790B2 (enExample)
EP (3) EP2336168A1 (enExample)
JP (7) JP3523650B2 (enExample)
KR (1) KR100496063B1 (enExample)
CN (1) CN1138786C (enExample)
AT (1) ATE328006T1 (enExample)
AU (1) AU735355B2 (enExample)
CA (2) CA2257247C (enExample)
CY (1) CY2010017I2 (enExample)
DE (2) DE69834699T3 (enExample)
DK (1) DK0911342T4 (enExample)
ES (1) ES2263204T5 (enExample)
FR (1) FR10C0048I2 (enExample)
HU (3) HU229841B1 (enExample)
IL (1) IL127115A (enExample)
LU (1) LU91759I2 (enExample)
NO (2) NO322632B1 (enExample)
NZ (1) NZ332995A (enExample)
PT (1) PT911342E (enExample)
RU (1) RU2238949C2 (enExample)
WO (1) WO1998046644A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
EP0946725B1 (en) 1996-12-23 2011-01-26 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE328006T1 (de) * 1997-04-15 2006-06-15 Sankyo Co Neues protein und verfahren zu dessen herstellung
SI0975754T2 (sl) * 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE412746T1 (de) * 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
CA2347107A1 (en) 1998-10-28 2000-05-04 Shinichi Mochizuki Bone-pathobolism treating agent
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) † 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
WO2002081521A2 (en) 2001-04-03 2002-10-17 Société des Produits Nestlé S.A. Osteoprotegerin in milk
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
EP1578305A4 (en) * 2002-12-10 2008-08-27 Schering Plough Ltd CANIN RANKL AND METHODS OF PREPARATION AND USE THEREOF
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
BR0318454A (pt) 2003-08-08 2006-09-12 Abgenix Inc anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2311873B1 (en) 2004-01-07 2018-08-29 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (ru) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Способ профилактики рождения больных остеопетрозом детей
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1991694T3 (da) * 2006-02-13 2016-08-01 Fluidigm Canada Inc Genekspressionsanalyse med grundstoftagget oligonukleotid
EP2020445B1 (en) 2006-05-12 2013-01-02 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
US20100105612A1 (en) 2006-10-11 2010-04-29 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
CN101772351B (zh) 2007-06-05 2013-01-02 东方酵母工业株式会社 新的骨量增加药
RU2475499C2 (ru) 2007-10-11 2013-02-20 Дайити Санкио Компани, Лимитед Антитело, направленное на белок siglec-15, связанный с остеокластами
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US9435811B2 (en) 2008-09-30 2016-09-06 Oriental Yeast Co., Ltd Inducer of chondrocyte proliferation and differentiation
CN102361632A (zh) * 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
CN106317224B (zh) 2009-04-09 2020-05-12 第一三共株式会社 抗-Siglec-15抗体
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
KR20130066682A (ko) 2010-10-05 2013-06-20 다이이찌 산쿄 가부시키가이샤 항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
JPWO2012133914A1 (ja) 2011-03-31 2014-07-28 オリエンタル酵母工業株式会社 Ｒａｎｋｌアンタゴニストを含む癌免疫増強剤
WO2013142186A1 (en) 2012-03-21 2013-09-26 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
SG11201405966PA (en) 2012-03-30 2014-11-27 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
CN105555291B (zh) 2013-08-07 2021-08-24 助育公司 用于治疗雄性不育症的抗体、化合物及其衍生物
US10357559B2 (en) 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2018052153A1 (ko) * 2016-09-13 2018-03-22 주식회사 이앤에스헬스케어 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN112521466B (zh) * 2020-01-22 2022-06-17 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0192658A4 (en) 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3356775B2 (ja) * 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1995007935A1 (en) 1993-09-14 1995-03-23 Merck & Co., Inc. cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) * 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
WO1998028423A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP0946725B1 (en) * 1996-12-23 2011-01-26 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE328006T1 (de) * 1997-04-15 2006-06-15 Sankyo Co Neues protein und verfahren zu dessen herstellung
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
SI0975754T2 (sl) 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
ES2287028T3 (es) 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PL222211B1 (pl) * 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Similar Documents

Publication Publication Date Title
JP2004041195A5 (enExample)
US20200181287A1 (en) Methods of purifying bispecific antibodies
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
JP2019195335A5 (enExample)
JP2011524740A5 (enExample)
JP2007530435A5 (enExample)
JP2020505919A5 (enExample)
RU2005137325A (ru) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
JP2009539348A5 (enExample)
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
WO2013088259A2 (en) Methods of purifying antibodies
US11945839B2 (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
JP2019502694A (ja) 二特異性抗体基幹
JP2025090679A5 (enExample)
JP2010508290A (ja) ヒトに適合するモノクローナル抗体に使用するための方法
CA2457362A1 (en) Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
JPWO2021139758A5 (enExample)
JP2008517605A5 (enExample)
US20220363782A1 (en) Orthogonal mutations for heterodimerization
RU98105631A (ru) Антитела против fas
Weidenhaupt et al. Functional mapping of conserved, surface‐exposed charges of antibody variable domains
JPWO2022129572A5 (enExample)
JP4471721B2 (ja) 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ
AU2018244638B2 (en) Methods and kits for determining binding sites
JPWO2022150788A5 (enExample)